The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APM | -23.49% | -97.53% | -52.29% | -99% |
| S&P | +15.4% | +78.67% | +12.31% | +172% |
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.
No news articles found for Aptorum Group.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $14.43M | 0.0% |
| Net Income | -$616.60K | 0.0% |
| EBITDA | -$589.63K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.27M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $3.50M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -36.11% | 0.0% |
No data available for this period.
| Metric | Q3 2025 | YoY Change |
|---|---|---|
| Price to Book | 0.54 | - |
| Price to Tangible Book Value | 0.54 | - |
| Enterprise Value to EBITDA | -10.68 | - |
| Total Debt | $3.50M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
